Megan Collett
Executive Director, Oncology Operations, APAC
Megan (Meg) Collett is Executive Director, Oncology Operations, APAC at Worldwide Clinical Trials, where she leads oncology clinical operations across the Asia-Pacific region. With more than 25 years of experience in clinical research, Meg is passionate about accelerating the development of innovative cancer therapies and expanding patient access to cutting-edge clinical trials.
Ask Megan a question
Submit an RFP. Ask a Question
In her current role, Meg partners with sponsors and study teams to deliver complex oncology programs throughout APAC, drawing on extensive experience in operational strategy, trial execution, and site engagement. Her expertise spans the full clinical development lifecycle, with particular focus on oncology studies requiring strong regional knowledge and close collaboration with investigators.
Before joining Worldwide in 2023, Meg served as Executive Director of Clinical Trials for the Ingham Institute for Applied Medical Research and South Western Sydney Local Health District, where she led the clinical trials support unit and advanced research capabilities across five major hospitals, providing patient access to more than 700 clinical trials. Through this work, she developed deep relationships with investigators, healthcare institutions, and research networks in oncology and hematology.
Meg's career spans hospitals, general practice, pharmaceutical and biotechnology companies, and contract research organizations. She has managed Phase I-IV trials across multiple therapeutic areas, including oncology, hematology, cardiology, neurology, immunology, and gastroenterology.
Prior to her time at the Ingham Institute, Meg spent eight years with IQVIA in senior leadership roles spanning Regulatory and Site Start-Up, Project Management, Functional Service Provision, Medical Writing, Data Management and Biostatistics, Medical Services, and Clinical Operations. She also led IQVIA Australia's Biotech Delivery Unit, which she helped establish to provide full-service Phase I-II clinical development support for emerging biotechnology companies.
